Jun 22, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
Jun 18, 2020
Almirall Announces FDA Approval Of Updated Label For Seysara® (Sarecycline) Tablets
May 29, 2020
Menlo Therapeutics Receives FDA Approval of ZILXI(TM) (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea
May 29, 2020
XTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
May 15, 2020
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
May 07, 2020
Acne Market Review 2016-2019 and Forecast to 2024
Apr 30, 2020
ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer
Mar 31, 2020
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
Mar 26, 2020
COSMEDIX Announces the Launch of Clean, Clinical Spot Treatment for Acne-Prone Skin
Feb 18, 2020
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
Feb 11, 2020
Dermata Therapeutics Announces Completion of Enrollment in a Phase 2b Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris
Jan 14, 2020
Foamix Announces AMZEEQ(TM) (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.
Jan 13, 2020
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Data On ARAZLO(TM) (tazarotene) Lotion, 0.045% In The Journal Of Drugs In Dermatology (JDD)
Jan 09, 2020
Foamix Announces AMZEEQ(TM) (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne
Dec 19, 2019
FDA Approves Ortho Dermatologics' ARAZLOTM (Tazarotene) Lotion, 0.045%, For Acne Vulgaris
Dec 06, 2019
Global Acne Drugs (Salicylic acid, Retin-A Micro, Onexton, and Solodyn) Market Report 2020
Nov 04, 2019
Foamix Announces Publication of AMZEEQ(TM) (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology
Oct 25, 2019
Sebacia Reports New Long-Term Real-World Results Demonstrating 92% Average Improvement in Acne at 24 Months
Oct 18, 2019
Foamix Receives FDA Approval of AMZEEQ(TM) Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
Oct 15, 2019
Bausch Health's Ortho Dermatologics Business To Present Data At The Fall Clinical Dermatology Conference